FDA rejects ITM's radiopharma therapy Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 11 August, 2026

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

presented by The de­bate of dura­bil­i­ty in nAMD

news Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatment Manufacturing problems cited in FDA rejection of ITM's radiopharma drug Trump calls for spacing out MMR vaccine into three shots, suggests it causes autism

Aug 19 1:00 pm ET From pilots to production: AI across R&D, safety, regulatory, and clinical sponsored by IBM Aug 27 12:00 pm ET Same molecule, different paths: Where value goes in cross-border dealmaking in a new era sponsored by PharmCube Sep 03 11:00 am ET How leading pharma organizations are putting AI agents to work sponsored by Medable

Scientist, Drug Discovery Data for AI/ML D. E. Shaw Research New York, NY, USA Machine Learning Researchers and Engineers D. E. Shaw Research New York, NY, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

ENDPOINTS PHARMA Judge blocks enforcement of WuXi AppTec's designation as Chinese military company Scholar Rock drops Novo manufacturing site from SMA drug application Bristol Myers details new $2.3B manufacturing campus in Houston

in case you missed it 1. Sionna's surprise cystic fibrosis trial failure sinks hopes of challenging Vertex 2. News Briefing RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win 3. AbCellera details 'striking' Phase 2 data for vasomotor symptoms treatment 4. Jazz bets on epilepsy again by acquiring Actio for $820M upfront 5. Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer 6. Exclusive: BioNTech vets get $25M seed funding for virtual cancer surveillance startup 7. How AstraZeneca’s $400B tie-up with US rival Bristol Myers unravelled